- NSMD1 has agreed to domicile its technology in Singapore, through kimbocorp, in order to complete research and development, product development, manufacturing and marketing of the device;
- kimbocorp is currently setting up the business and conducting due diligence on the founders and technology.
- NSMD1 needs to be ingrained in Singapore's Startup scene, in order to complete the Pre-Seed / Seed funding round, for the purpose of completing research and product development;
- Complete the research and development and product development in Singapore.
- NSMD1 technology must be verified and confirmed by government health and research agencies like A-Star and HSA;
- NSMD1 needs to complete the Series A funding round to mass-market and mass-produce in Singapore.
- NSMD needs to complete Series B funding to capture market share at scale.
Executive Summary of NSMD1
- NSMD1 is a non-invasive, extremely low frequency, neuronal stimulation medical device technology;
- NSMD1 potentially disrupts Transcranial Magnetic Stimulation (TMS), which is the best-known neuronal stimulation treatment on the market today for both stroke and traumatic brain injuries;
- TMS utilizes a field strength of 1-2 Teslas (10,000 Gauss = 1 Tesla). This is an abnormally high and unnatural field strength. Tesla strength fields are strong enough to cause grimaces, twitches and muscle contractions when applied transcranially. The natural field strength of the Earth is 25-65 milliGauss (1 milliGauss = one thousandth of a Gauss);
- NSMD1 utilises a natural magnetic field strength of 50 milliGauss.
TMS is not perfect
- TMS stimulates a small localized area of the brain. There are a number of risks associated with TMS. The most serious risks are fainting and the triggering of seizures. Other complications of therapy include discomfort or pain at the stimulation site, headache, spasms, twitching, transient induction of hypomania, transient cognitive changes, transient hearing loss and transient impairment of working memory. These adverse events are related directly to the abnormal power of the technology (200,000-400,000 stronger than the NSMD1).
NSMD1 is cheap and afforable compared to TMS
- TMS is an in-office medical treatment typically requiring many office visits (like a dialysis) at a mean cost of $500 per treatment. Initial capital costs for a clinician for one TMS delivery system ranges from $75K-$150K;
- The NS1, a superior device, will be provided to clinicians at no cost. NSMD1 will earn income from a profit-sharing or leasing agreement with clinicians. Following in-office treatments, clinicians will have the ability to prescribe the NSMD1 as an at-home technology with patients either renting or purchasing a device from the clinician.
NSMD1 is digitally-enabled
- The NSMD1 will be controlled by a “Smart App” ensuring the company full control over the device usage and billing;
- The APP will allow for the following features:
- Downloads available for both Apple and Android operating system;
- WIFI connectivity;
- Activation and control of the device;
- Registration of patient information
- Tracking of treatment timelines;
- Direct billing to insurance providers;
- Payment options such as Paypal;
- Credit Card payment options;
- Payment of Physicians treatment fees through direct deposit;
- Product registration through barcode scanning;
- Sub-file APP sharing (so Dr’s can send a patient a download link under the clinics umbrella to use the device at home and maintain billing and tracking information)
- There are 9,500 cases of strokes each year in Singapore. which equates to about 26 cases per day;
- A stroke occurs when a part of the brain gets damaged due to an interruption in its blood supply. When brain cells die because they do not receive oxygen from blood, it is irreversible.
- Stroke remains the fourth leading cause of death in Singapore and one of the top contributors of adult disability;
- Those who survive a stroke are often left with severe disabilities such as cognitive problems, inability to speak or understand speech, loss of vision, numbness in the face, arms, or legs, and paralysis. A common result of stroke is depression;
- Traumatic brain injuries is the fifth leading cause of death in Singapore. About 108-322 per 100,000 people suffers from TBI.
- NSMD1 is free of charge for clinics to use and leased to patients at home after approval by the clinics;
- NSMD1 is also digitally enabled and tracked through an admin dashboard;
- The business model allows rapid scalability and ability to capture market segments in wholes.
Unique opportunity to leave behind a legacy
Leave us a message
if you are interested to help this novel technology and benefit thousands others.